Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine
| Autor: | Maria de Lourdes de Sousa Maia, Andréa Teixeira-Carvalho, Larissa Chaves Freire, Thalles Souza-Lopes, Laise Rodrigues Reis, Ana Carolina Campi-Azevedo, Tatiana Guimarães de Noronha, Alessandro Pecego Martins Romano, Akira Homma, Janaina Reis Xavier, Jordana Rodrigues Barbosa Fradico, Reinaldo de Menezes Martins, Jordana Grazziela Alves Coelho-dos-Reis, Roberto Henrique Guedes Farias, Thalita da Matta de Castro, Ismael Artur da Costa-Rocha, Vanessa Peruhype-Magalhães, Elizabeth Maciel de Albuquerque, Olindo Assis Martins-Filho, Luiz Antonio Bastos Camacho, Carla Magda Allan Santos Domingues, Christiane Costa-Pereira, Sheila Maria Barbosa de Lima, Juliana Vaz de Melo Mambrini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine lcsh:Immunologic diseases. Allergy Cellular immunity Primary vaccination Immunology Yellow fever vaccine Immunological memory cellular memory 03 medical and health sciences 0302 clinical medicine Double-Blind Method Immunity 17DD vaccine Yellow Fever Humans Medicine Immunology and Allergy neutralizing antibodies Original Research Dose-Response Relationship Drug biology business.industry Yellow Fever Vaccine Yellow fever Antibody titer Correction medicine.disease Antibodies Neutralizing 3. Good health 030104 developmental biology biology.protein Antibody business lcsh:RC581-607 Immunologic Memory subdoses Follow-Up Studies 030215 immunology medicine.drug |
| Zdroj: | Frontiers in Immunology, Vol 10 (2019) Frontiers in Immunology |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2019.02433 |
| Popis: | The present study aims to determine whether 17DD-YF-specific humoral and cellular immunological memory is maintained 8-years after primary vaccination with subdoses (10,447IU;3,013IU;587IU;158IU;31IU). For this purpose, this follow-up study was carried out in a subset of volunteers (n = 98) originally enrolled in the dose-response study in 2009 and 46 non-vaccinated controls. Our results demonstrated that vaccinees, who had seroconverted following primary vaccination and had not been revaccinated, present similar neutralizing antibodies levels and YF-specific cellular memory, particularly CMCD4 and EMCD8 as compared to the reference full dose (27,476IU). Although, PRNT seropositivity rates were similar across subgroups (94, 82, 83, 94, 80, and 91%, correspondingly), only doses above 587IU elicited similar iterative proportion of seropositivity rates, calculated as a progressive decrease on seropositivity rates along time (89, 80, 80, and 91%, respectively) as compared to 158IU and 31IU (68 and 46%, respectively). Noteworthy were the strong positive correlations ("EMCD4,EMCD8" and "TNFCD8,IFNCD8") observed in most subdoses, except for 31IU. Major similarities underscored the preserved antibody titers and the outstanding levels of EMCD8, relevant correlates of protection for YF-specific immunity. These findings provide evidences to support the regular use of dose sparing strategy for YF vaccine in adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|